ABSTRACT
BACKGROUND AND OBJECTIVES: Topical 5-aminolevulinic acid-mediated photodynamic therapy (topical ALA-PDT) using a 635-nm light-emitting diode (LED) light is an effective treatment modality for oral verrucous hyperplasia. This study tested whether topical ALA-PDT using either the LED or laser light was also an effective treatment modality for oral erythroleukoplakia (OEL) lesions. STUDY DESIGN/MATERIALS AND METHODS: In this prospective but non-randomized study, 20 OEL lesions were treated with topical ALA-PDT using the 635-nm LED light and 26 OEL lesions were treated with topical ALA-PDT using the 635-nm laser light. The difference in clinical outcomes was compared between the two groups by Fisher exact test. RESULTS: We found that the 20 LED light-treated OEL lesions showed complete response (CR) in 17 and partial response (PR) in 3. The 17 CR OEL lesions required an average of 3.7 (range, 2-7) treatments of ALA-PDT to achieve CR of the lesions. The 26 laser light-treated OEL lesions showed CR in 25 and PR in 1. The 25 CR OEL lesions needed an average of 3.3 (range, 2-6) treatments of ALA-PDT to achieve CR of the lesions. There was no significant difference in PDT outcomes between the 20 LED light-treated and 26 laser light-treated OEL lesions (P = 0.303). When the 42 CR OEL lesions were pooled together, we found that smaller lesions (greatest diameter <1.5 cm) and lesions with thinner surface keratin (keratin layer < or =30 microm) needed significantly fewer mean treatment number of PDT to achieve a CR than the larger lesions (P = 0.000) and lesions with thicker surface keratin (P = 0.000), respectively. CONCLUSIONS: Topical ALA-PDT using either the LED or laser light is an effective treatment modality for OEL lesions. There is no significant difference in clinical outcomes of OEL lesions treated with PDT using either the LED or laser light.
Subject(s)
Erythroplasia/radiotherapy , Lasers, Semiconductor/therapeutic use , Leukoplakia, Oral/radiotherapy , Low-Level Light Therapy , Photochemotherapy/methods , Adult , Aged , Aged, 80 and over , Aminolevulinic Acid/administration & dosage , Erythroplasia/pathology , Female , Follow-Up Studies , Humans , Leukoplakia, Oral/pathology , Male , Middle Aged , Photosensitizing Agents/administration & dosage , Prospective Studies , Treatment OutcomeSubject(s)
Erythroplasia/pathology , Erythroplasia/radiotherapy , Low-Level Light Therapy/methods , Penile Neoplasms/pathology , Penile Neoplasms/radiotherapy , Adult , Aged , Carbon Dioxide/therapeutic use , Cohort Studies , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Risk Assessment , Treatment OutcomeABSTRACT
The therapeutic results obtained with soft-X-ray irradiation on 77 lesions in 52 patients are reported. 35 males (67.3%) and 17 females (32.7%) were treated. Clinical and histological features revealed Bowen's disease in 73 cases (94.8%) and erythroplasia of Queyrat in 4 cases (5.2%). The primary healing was rated as 100% in all cases up to 6 months after a cumulative dosage of 3,200-5,000 R. 2 cases with a genital localization (2.6% of all sites and 11.1% of anogenital localizations) relapsed after 8 and 16 months, respectively. The follow-up period ranged from 1 to 11 years with a mean of 3 years. In order not to miss the late recurrences, the oncologic follow-up is taken care of by the Dermatology Department of the Zurich University Hospital during 10 years, or longer in some cases. Association with a malignant internal tumour (larynx, bronchi, anus) was found in 3 patients (5.8%).
Subject(s)
Bowen's Disease/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Erythroplasia/radiotherapy , Radiotherapy , X-Ray Therapy , Adult , Aged , Bowen's Disease/complications , Erythroplasia/complications , Female , Humans , Male , Middle Aged , Penile Diseases/radiotherapy , Radiotherapy Dosage , Vulvar Diseases/radiotherapyABSTRACT
Report on empirical data of X-ray treatment of dermatoses in the genital area, concerning indications, technique and results. Irradiations are mainly successful in large patches of Bowen's disease and Bowen's carcinoma as well as in Queyrat's erythroplasia and Paget's disease. Carcinomata of the penis should not exceed the stages T1-T2. Regression of Peyronie's disease is accelerated. Psoriatic lesions disappear following Grenz-rays without further topical treatment. Grenz-rays can also prevent or delay local recurrences of herpes simplex eruptions in the genital area.
